tldrdaily.news logo
Tag

Car T

All articles tagged with #car t

business5 days ago

Gilead to Acquire Arcellx for $7.8B to Accelerate Anito-cel and CAR-T Platform

Gilead will acquire Arcellx for $115 per share in cash plus a $5-per-share contingent value right (CVR), valuing the deal at about $7.8 billion and giving Gilead full control of Anito-cel, its BCMA-directed CAR-T therapy for multiple myeloma. The transaction aims to accelerate development and commercialization, with Anito-cel’s BLA accepted by the FDA and a PDUFA date of December 23, 2026; the deal is expected to close in Q2 2026 and to be accretive to EPS after FDA approval, with the CVR tied to cumulative global net sales milestones through 2029.

via Gilead Sciences|
#anito-cel#arcellx#business
Gilead buys Arcellx for $7.8B to bolster CAR-T push against Carvykti
business5 days ago

Gilead buys Arcellx for $7.8B to bolster CAR-T push against Carvykti

Gilead agreed to acquire Arcellx for about $7.8 billion in cash to take full control of the BCMA-targeted CAR-T therapy anito-cel as FDA review proceeds, paying $115 a share—a 68% premium to Arcellx's 30-day VWAP with a $5-per-share contingent payout if global sales reach $6 billion by 2029; the deal aims to sharpen Gilead's cell-therapy portfolio and compete with J&J/Legend's Carvykti, with analysts noting anito-cel's safety profile and potential to restore momentum for Gilead's Kite unit.

via Fierce Biotech|
#biotech#business#car-t
Gilead to Acquire Arcellx in $7.8 Billion CAR-T Focused Deal
business5 days ago

Gilead to Acquire Arcellx in $7.8 Billion CAR-T Focused Deal

Gilead will buy Arcellx for $7.8 billion in cash, valuing Arcellx at $115 per share with a 79% premium and expanding their joint development of the anti-cancer CAR-T therapy anito-cel for multiple myeloma. The deal follows Arcellx's collaboration with Kite Pharma, and the FDA is reviewing anito-cel with a decision expected by year-end. The acquisition is expected to be EPS-accretive in 2028 and includes a $5 per share milestone payment if cumulative global net sales of anito-cel reach $6 billion through 2029.

via CNBC|
#arcellx#biotech#business
Lilly to Acquire Orna Therapeutics to Accelerate In Vivo CAR-T
biotech-healthcare19 days ago

Lilly to Acquire Orna Therapeutics to Accelerate In Vivo CAR-T

Eli Lilly will acquire Orna Therapeutics in a deal worth up to $2.4 billion in cash, expanding Lilly’s genetic-medicine platform with Orna’s circular-RNA–based in vivo CAR-T technology (ORN-252) designed to treat B cell–driven autoimmune diseases, leveraging lipid nanoparticle delivery for potentially more durable therapeutic protein expression and broader in vivo cell-therapy options.

via PR Newswire|
#biotech-healthcare#car-t#circular-rna
Twenty Years of Cancer Advances Raise U.S. Five-Year Survival to 70%
science1 month ago

Twenty Years of Cancer Advances Raise U.S. Five-Year Survival to 70%

A 75th American Cancer Society Cancer Statistics report shows the U.S. five-year cancer survival rate has risen to about 70% (7‑in‑10) thanks to earlier detection and new treatments like immune checkpoint therapy and CAR‑T cell therapy. Survival has improved across cancers (breast 92%, melanoma 95%, prostate 98%), with leukemia and non‑Hodgkin lymphoma up ~20% and 18% and pancreatic and liver cancers also rising (to 13% and 22%). Myeloma and lung cancer survival have climbed to 62% and 15–28%, while late-stage survival now averages 35% (up from 17%). The death rate has fallen about 34% since 1991, saving roughly 4.8 million lives by 2023 — achievements driven by diagnosis, screening, and innovative therapies rather than a cure.

via Good News Network|
#cancer-research#cancer-survival#car-t
NHS administers pioneering CAR-T leukemia therapy to first patient, hailed as sci‑fi
health1 month ago

NHS administers pioneering CAR-T leukemia therapy to first patient, hailed as sci‑fi

The NHS has funded and begun delivering CAR-T cell therapy for adults with B‑cell ALL, with 28‑year‑old Oscar Murphy receiving the first infusion in Manchester. The personalised “living drug” reprograms a patient’s T‑cells to attack cancer and could extend survival; trial data showed 77% remission and about 15.6 months of added life, with around 50 patients a year expected to benefit across the UK.

via BBC|
#cancer#car-t#health
"CAR T-Cell Therapy Shows Promise as One-Shot Asthma Cure in Mice"
health1 year ago

"CAR T-Cell Therapy Shows Promise as One-Shot Asthma Cure in Mice"

Chinese scientists have developed a pioneering CAR-T cell therapy that offers the potential for a one-time treatment for asthma, a condition that currently requires lifelong management. This therapy, which targets key cytokines driving asthma, has shown promising results in animal studies, providing long-term relief from symptoms. While the findings are encouraging, experts stress the need for further research to ensure the therapy's safety and efficacy in humans.

via Interesting Engineering|
#asthma#car-t#cell-therapy
"FDA Pushes for 'Boxed Warning' on CAR-T Cancer Therapies"
health-pharmaceuticals2 years ago

"FDA Pushes for 'Boxed Warning' on CAR-T Cancer Therapies"

The US FDA has requested a "boxed warning" to be added to the prescribing information for CAR-T cancer therapies, including those made by Gilead Sciences, Johnson & Johnson, Novartis, and others, due to reports of patients developing T-cell blood cancer after treatment. Novartis has agreed to update the prescribing information for its CAR-T cell therapy Kymriah, while Bristol Myers is evaluating next steps for its therapies. The FDA has identified adverse events and clinical trial reports describing T-cell malignancies and considers the risks applicable to all therapies in the category.

via Reuters|
#cancer-therapies#car-t#fda
"Allogene Shifts Gears with New Strategy and Partnerships in Cell Therapy for Blood Cancer Amid Workforce Reduction"
health-and-medicine2 years ago

"Allogene Shifts Gears with New Strategy and Partnerships in Cell Therapy for Blood Cancer Amid Workforce Reduction"

Allogene Therapeutics is altering its development strategy for ALLO-501A, an off-the-shelf cell therapy for blood cancer, due to intense competition from personalized CAR-T treatments. The company is discontinuing two ongoing clinical trials for patients with advanced-stage lymphoma and instead will initiate a new study targeting newly diagnosed high-risk lymphoma patients. This shift aims to position ALLO-501A more effectively in the competitive blood cancer treatment landscape.

via STAT|
##allogenetherapeutics#bloodcancer
health2 years ago

Israeli cancer treatment boasts 90% success rate.

Hadassah-University Medical Center in Jerusalem has developed a groundbreaking treatment for multiple myeloma cancer using genetic engineering technology called CAR-T, which boosts the patient’s own immune system to destroy the cancer. Over 90% of the 74 patients treated at Hadassah went into complete remission. The treatment is still being conducted as an experiment, with a waiting list of over 200 patients from Israel and various parts of the world. The experimental treatment will also be provided throughout the US in the coming months.

via The Jerusalem Post|
#cancer-treatment#car-t#genetic-engineering